11 research outputs found
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
Get PDFAim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.
Clinical trial registration: NCT02761187 (ClinicalTrials.gov
From mathematical model towards educational simulation game of hemodynamics of cardiovascular system
No full textDevelopment of In-Browser Simulators for Medical Education: Introduction of a Novel Software Toolchain
No full textXylic substrates at the fossilisation barrier: oak trunks (Quercus sp.) in the Holocene sediments of the Labe River, Czech Republic
No full textIxazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
No full textAim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)</ext-link. © 2021 Future Medicine Ltd.. All rights reserved
Carbohydrate epitopes as a cause of cross-reactivity in patients allergic to Hymenoptera venom
No full textAssignment of sigma factors of RNA polymerase to promoters in Corynebacterium glutamicum
No full textEarly postglacial recolonisation, refugial dynamics and the origin of a major biodiversity hotspot. A case study from the Malá Fatra mountains, Western Carpathians, Slovakia
No full textStrategy of a top agriculture co-operative in the central planned economy. The differentiation of the organization in perspective social system theory
No full text
